
Althea Patents Method to Crystallize Proteins
The company’s method reduces the time required to crystallize antibodies from weeks to one day.
Contract development and manufacturing organization (CDMO) Ajinomoto Althea announced on May 17, 2016 that the United States Patent and Trademark Office (USPTO) has issued the company a patent covering methods to crystallize monoclonal antibodies (mAbs) for the purposes of stabilization, storage, and safe delivery of active antibody crystals.
The
The technology works for mAbs, recombinant proteins, peptides, vaccines, DNA, and antibiotics, although the patent only specifically covers whole antibody crystals. It was developed to resolve issues related to viscosity, aggregation, and stability of complex biologic therapeutics. The technology will help prevent the chemical and physical denaturation that can occur during product manufacture and storage, and according to a company
In summary, the patent states, “The process of crystallization of whole antibodies serves not only as a powerful protein purification or stabilization tool but also affords the most concentrated protein form possible.”
Source: Ajinomoto Althea, USPTO
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.